OBJECTIVE: The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associated rhabdomyolysis. METHODS: This study had two components: a candidate gene study to evaluate variants in CYP2C8, UGT1A1, UGT1A3, and SLCO1B1; and a genome-wide association study to identify risk factors in other regions of the genome. A total of 185 rhabdomyolysis cases were frequency matched to statin-using controls from the Cardiovascular Health Study (n=374) and the Heart and Vascular Health Study (n=358). Validation relied on functional studies. RESULTS: Permutation test results suggested an association between cerivastatin-associated rhabdomyolysis and variants in SLCO1B1 (P=0.002), but not variants in CYP2C8 (P=0.073) or UGTs (P=0.523). An additional copy of the minor allele of SLCO1B1 rs4149056 (p.Val174Ala) was associated with the risk of rhabdomyolysis (odds ratio: 1.89; 95% confidence interval: 1.40-2.56). In transfected cells, this variant reduced cerivastatin transport by 40% compared with the reference transporter (P<0.001). The genome-wide association study identified an intronic variant (rs2819742) in the ryanodine receptor 2 gene (RYR2) as significant (P=1.74E-07). An additional copy of the minor allele of the RYR2 variant was associated with a reduced risk of rhabdomyolysis (odds ratio: 0.48; 95% confidence interval: 0.36-0.63). CONCLUSION: We identified modest genetic risk factors for an extreme response to cerivastatin. Disabling genetic variants in the candidate genes were not responsible for the bimodal response to cerivastatin.
OBJECTIVE: The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associated rhabdomyolysis. METHODS: This study had two components: a candidate gene study to evaluate variants in CYP2C8, UGT1A1, UGT1A3, and SLCO1B1; and a genome-wide association study to identify risk factors in other regions of the genome. A total of 185 rhabdomyolysis cases were frequency matched to statin-using controls from the Cardiovascular Health Study (n=374) and the Heart and Vascular Health Study (n=358). Validation relied on functional studies. RESULTS: Permutation test results suggested an association between cerivastatin-associated rhabdomyolysis and variants in SLCO1B1 (P=0.002), but not variants in CYP2C8 (P=0.073) or UGTs (P=0.523). An additional copy of the minor allele of SLCO1B1 rs4149056 (p.Val174Ala) was associated with the risk of rhabdomyolysis (odds ratio: 1.89; 95% confidence interval: 1.40-2.56). In transfected cells, this variant reduced cerivastatin transport by 40% compared with the reference transporter (P<0.001). The genome-wide association study identified an intronic variant (rs2819742) in the ryanodine receptor 2 gene (RYR2) as significant (P=1.74E-07). An additional copy of the minor allele of the RYR2 variant was associated with a reduced risk of rhabdomyolysis (odds ratio: 0.48; 95% confidence interval: 0.36-0.63). CONCLUSION: We identified modest genetic risk factors for an extreme response to cerivastatin. Disabling genetic variants in the candidate genes were not responsible for the bimodal response to cerivastatin.
Authors: Mikko Niemi; Janne T Backman; Lauri I Kajosaari; Julian B Leathart; Mikko Neuvonen; Ann K Daly; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen Journal: Clin Pharmacol Ther Date: 2005-06 Impact factor: 6.875
Authors: Russell A Wilke; Debbie W Lin; Dan M Roden; Paul B Watkins; David Flockhart; Issam Zineh; Kathleen M Giacomini; Ronald M Krauss Journal: Nat Rev Drug Discov Date: 2007-11 Impact factor: 84.694
Authors: Susan E Andrade; David J Graham; Judy A Staffa; Stephanie D Schech; Deborah Shatin; Lois La Grenade; Michael J Goodman; Richard Platt; Jerry H Gurwitz; K Arnold Chan Journal: J Clin Epidemiol Date: 2005-02 Impact factor: 6.437
Authors: Christopher H George; Sarah A Rogers; Benedicte M A Bertrand; Richard E A Tunwell; N Lowri Thomas; Derek S Steele; Eryl V Cox; Christopher Pepper; Carolyn J Hazeel; William C Claycomb; F Anthony Lai Journal: Circ Res Date: 2007-02-22 Impact factor: 17.367
Authors: Nicholas L Smith; Lucia A Hindorff; Susan R Heckbert; Rozenn N Lemaitre; Kristin D Marciante; Kenneth Rice; Thomas Lumley; Joshua C Bis; Kerri L Wiggins; Frits R Rosendaal; Bruce M Psaty Journal: JAMA Date: 2007-02-07 Impact factor: 56.272
Authors: Liam R Brunham; Steven Baker; Andrew Mammen; G B John Mancini; Robert S Rosenson Journal: Cardiovasc Res Date: 2018-07-01 Impact factor: 10.787
Authors: Bani Tamraz; Hisayo Fukushima; Alan R Wolfe; Rüdiger Kaspera; Rheem A Totah; James S Floyd; Benjamin Ma; Catherine Chu; Kristin D Marciante; Susan R Heckbert; Bruce M Psaty; Deanna L Kroetz; Pui-Yan Kwok Journal: Pharmacogenet Genomics Date: 2013-07 Impact factor: 2.089
Authors: Frank S Ong; Joshua L Deignan; Jane Z Kuo; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody; Kingshuk Das Journal: Pharmacogenomics Date: 2012-03 Impact factor: 2.533
Authors: Najmeh Ahangari; Mohammad Doosti; Majid Ghayour Mobarhan; Amirhossein Sahebkar; Gordon A Ferns; Alireza Pasdar Journal: Ann Med Date: 2020-08-24 Impact factor: 4.709